Compare Davita Inc (DVA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Vanguard S&P 500 ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Vanguard S&P 500 ETF trades at $714.18 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 159.6× Davita Inc's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Vanguard S&P 500 ETF for 55 Days on average.
| DVA | VOO | |
|---|---|---|
Market Cap | $11.28B | $1.80T |
Volume | 650,294 | 4,660,398 |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $716.17 |
52-Week Low | $103.87 | $580.93 |
Typical Hold Time | 113 Days | 55 Days |
Enterprise Value | $24.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
VOO trades at $714.42, down 0.24% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF's dividend yield is modest, and recent news highlights its role in long-term wealth building amid expectations of slowing S&P 500 profit growth. Short interest increased 46.9% in September, indicating some bearish sentiment.
The outlook for VOO remains positive for buy-and-hold investors, supported by its low-cost exposure to the S&P 500. Risks include macroeconomic headwinds from potential Fed rate hikes and elevated short interest. Analyst consensus favors long-term holding, with the ETF seen as a core portfolio component for diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
